Methods The patients were randomly divided into group A or into group B.The patients of group A were injected with Botulinum toxin A(BTA) in blepharoes and hemiface,the density was 5.0u/0.1ml. The density for group B was 2.25u/0.1ml.
Methods Eight cases with Hirschsprung disease were proven pathologically or diagnosed by barium enema. At the clock point of 3,6,9 under supine posture,a total dose of 1.5 U/kg of botulinum toxin A was injected into the internal anal sphincter and the submucosa of rectum.
Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain.
According to this scheme, the effectiveness of botulinum toxin A in the treatment of sialorrhoea is considered established (level A).
Use of Botulinum toxin A (BT.-A), for the same in the past, has been quite successful without many reported side effects.
Botulinum toxin A (BTX) injections have been used successfully in the treatment of post-stroke foot spasticity, but the optimal dose-response relationship for selected muscles has yet to be established.
The patient was treated with medical therapy (botulinum toxin A) and surgery.